BALTIMORE, MD -- (Marketwired) -- 07/18/13 -- Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that while much of the attention of the use of these nutrients is on wellness and disease prevention, Plandaí Biotechnology Inc.'s (OTCQB: PLPL) flagship product, Phytofare Catechin Complex, might prove its effectiveness in increasing our cognitive abilities as well.
Studies and research performed in the 1990's in recent years confirmed the fact that due to EGCG's ability to easily cross the blood brain barrier and increasing brain activity up to 2 hours after ingestion, EGCG's cognitive properties have been investigated in animal studies. When administered via IV to rats, EGCG statistical significance was witnessed at high doses one hour prior to a learning event. Plus, lower doses fed orally for eight weeks indicated an improvement in memory in aged rates.
Moreover, a study using a combination of green tea catechins and L-theanine, a constituent of green tea, demonstrated that patients suffering from non-clinical memory decline (average age 58) increasing recognition speed, word reading, and selective attention.
Clearly, whether EGCG is used alone or in conjunction with L-theanine, cognitive abilities can be aided via consumption of these nutrients. This opens up a whole new market for a company such as Plandaí that has demonstrated an ability to generate substantial bioavailability in botanical extracts, including green tea, which is key in leveraging the huge opportunity with Baby Boomers, the aging, and the younger set, which are prime targets for wellness and cognitive health.
Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented Phytofare extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Goldman Small Cap Research
Most Popular Stories
- Koch Brothers Step up Anti-Obamacare Campaign
- Obama Administration Releases Proposal to Regulate For-Profit Colleges
- Elizabeth Vargas' Husband Marc Cohn Addresses Rumors
- Keurig Adds Peet's coffee, Alters Starbucks deal
- Quiznos Files for Chapter 11
- U.S. to Relinquish Gov't Control Over Internet
- SoCalGas Reaches Record Spend on Diversity Suppliers
- FDIC Sues Big Banks Over Rate Manipulation
- U.S. Consumer Sentiment Falls in Early March
- Vybz Kartel Convicted of Murder